MedTrace Logo

Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)

NCT04866082 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 466

Last updated 2023-02-22

No results posted yet for this study

Summary

Brief Summary: Administration of systemic corticosteroids for patients with severe forms of severe acute respiratory syndrome in coronavirus-2 (SARS-CoV-2) infection are recommended by several guidelines. In the very beginning of SARS-CoV-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) ARDS, despite previous data and clinical practice for patients with refractory or severe form of acute respiratory distress syndrome (ARDS). But recently after publication of RECOVERY trial (Randomized Evaluation of Covid-19 Therapy, July 2020) and ensued metaanalysis of World Health Organization (WHO) working group, routine administration of systemic corticosteroids was revisited. However, there is an ongoing debate regarding evidence supporting the dose, type of administration (bolus vs. continuous infusion), timing and type of corticosteroids. Ongoing randomized controlled trials (RCTs) are challenging the recommendation of 6 mg of dexamethasone for all patients with severe form of COVID-19. Due to the dynamics of COVID-19 surges and rapid issuing of official recommendations, daily clinical practice of systemic corticosteroids administration can vary. An electronic evaluation form containing 20 questions will be sent to European Society of Intensive Care (ESICM) and European Society of Anaesthesiology and Intensive Care (ESAIC) members. Participants will be asked to describe their routine clinical practice regarding administration of systemic corticosteroids among patients with COVID-19 ARDS.

Conditions

  • Severe COVID-19

Interventions

OTHER

questionnaire

Members of European Society of Intensive Care and European Society of ANaesthesiology and Intensive care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS

Sponsors & Collaborators

  • European Society of Intensive Care Medicine

    collaborator OTHER

  • European Society of Anaesthesiology and Intensive Care

    collaborator OTHER

  • Brno University Hospital

    lead OTHER

Principal Investigators

  • Jan Malaska, assoc. prof. MD., Ph.D. · University Hospital Brno

  • Petr Stourac, prof.MD.Ph.D. · Faculty of medicince Masaryk University and University Hospital Brno

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-30
Primary Completion
2022-06-14
Completion
2022-06-30

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04866082 on ClinicalTrials.gov